- Data on ARIUS' novel CD9 therapeutic antibody to be presented at AACR
Special Conference on Cancer Stem Cells -
TORONTO, Feb. 13 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new information on the preclinical activity of its anti-CD9 cancer stem cell antibody will be presented at the AACR Special Conference on Cancer Stem Cells entitled "The Role of Cancer Stem Cells in the Initiation and Propagation of Tumorigenesis," held on February 12th-15th in Los Angeles. The Company will disclose data demonstrating that its CD9 antibody not only targets leukemia cancer stem cells, but also leads to a dramatic reduction in their capacity to self-renew or give rise to further leukemia. These findings were discovered in collaboration with John E. Dick, PhD, the Canada Research Chair in Stem Cell Biology with the University Health Network in Toronto, Canada.
The poster presentation (Wednesday, February 13th 2008, from 4:30-6:30 pm) will outline the activity of ARIUS' anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). The long-term survival expectation for patients with AML is poor due to disease relapse and resistance to chemotherapy. CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which often survive treatment, continue to multiply and go on to seed new tumors. Studies of patients with different types of cancer have demonstrated that the presence of CD9 can be linked to lower survival rates. AR40A746.2.3 has previously been found to control tumor growth and improve survival in pre-clinical breast and pancreatic cancer models.
"Since some cancer stem cells have been shown to be highly resistant to
traditional cancer therapies and are believed to contribute to treatment
resistance, the selectivity of ARIUS' anti-CD9 antibody for leukemic cancer
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved